Cantabio Pharmaceuticals, Inc. (CTBO) Research

Cantabio Pharmaceuticals, Inc. is a preclinical biotechnology company dedicated to the discovery, development, and commercialization of innovative therapeutic solutions for Parkinson's disease (PD), Alzheimer's disease (AD), and related neurological conditions. The company's key development programs feature CB101, a small molecule pharmacological chaperone that targets DJ-1 for PD treatment; CB201, an engineered DJ-1 protein designed to penetrate the central nervous system, also for PD; CB301, a small molecule pharmacological chaperone aimed at the Tau protein for AD; and CB401, another small molecule pharmacological chaperone targeting Aß for AD. Furthermore, Cantabio Pharmaceuticals has a collaborative agreement with the Luxembourg Institute of Health, focusing on researching the therapeutic application of the DJ-1 protein for immune-associated diseases. The company, founded in 2009, is situated in Palo Alto, California.

Open Cantabio Pharmaceuticals, Inc. (CTBO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.